Genelux Reports $26.3M Cash Runway into Q1 2027 and Advances Olvi-Vec Trials
Genelux closed Q1 with $26.3M cash, funding into Q1 2027, while R&D expenses rose by $1.1M to $5.8M. It confirmed Phase 3 OnPrime/GOG-3076 ovarian trial topline data in 2H26 and reported 33% response rate in Phase 1b/2 SCLC and 60% disease control in Phase 2 NSCLC.
1. Financial Results
As of March 31, 2026, Genelux held $26.3 million in cash, cash equivalents, marketable securities and restricted cash, expected to fund operations into the first quarter of 2027. R&D expenses increased by $1.1 million year-over-year to $5.8 million, driven primarily by higher clinical and regulatory costs.
2. Phase 3 OnPrime/GOG-3076 Trial
The randomized Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer remains on track for topline data in the second half of 2026. This registrational study compares Olvi-Vec primed immunochemotherapy plus platinum-doublet and bevacizumab against physician’s choice chemotherapy plus bevacizumab.
3. Lung Cancer Program Updates
In the Phase 1b/2 SCLC study, Olvi-Vec achieved a 33% partial response rate (3/9 patients) with tumor shrinkage up to 85% and a 67% disease control rate. In the Phase 2 NSCLC VIRO-25 study, three of five evaluable patients (60%) achieved disease control, with tumor size reductions up to 22.7%.
4. Manufacturing and Commercial Readiness
Genelux is advancing its manufacturing capabilities to support Olvi-Vec scale-up and potential commercialization, focusing on supply, quality and organizational infrastructure as registration-directed programs progress.